General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Hidradenitis Suppurativa
Last updated October 23, 2017
Invokamet (canagliflozin/metformin hydrochloride)
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated October 20, 2017
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis
Last updated October 17, 2017
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Osteoporosis in Men
Last updated October 17, 2017
Status:
Concluded without agreement
Manufacturer:
Mylan Pharmaceuticals LLC
Indication:
Alcohol Abstinence
Last updated September 29, 2017
Truvada (emtricitabine/tenofovir disoproxil fumarate)
Status:
Negotiations were not pursued
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
HIV-1 infection, pre-exposure prophylaxis
Last updated September 8, 2017
Status:
Concluded without agreement
Manufacturer:
Celgene Inc.
Indication:
Psoriatic Arthritis
Last updated September 8, 2017
Status:
Concluded without agreement
Manufacturer:
Celgene Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated September 8, 2017
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Neuroendocrine tumours of Gastrointestinal or Lung origin
Last updated September 1, 2017
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Platinum-Resistant Ovarian Cancer
Last updated August 21, 2017